INSM
NASDAQ · Biotechnology
Insmed Inc
$129.38
+30.36 (+30.66%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-13.48%
1Y
+18.37%
YTD
-26.95%
Open$128.22
Previous Close$99.02
Day High$137.70
Day Low$126.15
52W High$212.75
52W Low$90.39
Volume—
Avg Volume2.13M
Market Cap21.12B
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$168.11
Below
SMA 200
$139.54
Below
RSI (14)
54.8
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
29 analysts
Price Target
+10.8% upside
Current
$129.38
$129.38
Target
$143.40
$143.40
$91.17
$143.40 avg
$177.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 652.76M | 482.81M | 44.36B |
| Net Income | -1,374,356,713 | -914,882,427 | 1.08B |
| Profit Margin | -210.5% | -200.0% | 2.4% |
| EBITDA | -1,335,603,517 | -938,478,802 | 2.00B |
| Free Cash Flow | — | — | 843.11M |
| Rev Growth | +35.2% | +35.2% | +19.4% |
| Debt/Equity | 0.99 | 0.99 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $244.33 | -0.76% | 122.9 | 446.67B |
| AMGN | Amgen Inc | $403.48 | -1.07% | 26.5 | 206.48B |
| GILD | Gilead Sciences Inc | $129.97 | -1.36% | 17.6 | 161.72B |
| VRTX | Vertex Pharmaceuticals Inc | $484.53 | -0.06% | 27.8 | 120.52B |
| REGN | Regeneron Pharmaceuticals | $767.54 | -0.14% | 17.5 | 77.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $217.83 | -4.76% | 47.7 | 27.52B |